All Updates

All Updates

icon
Filter
Partnerships
BioStrand collaborates with PGxAI to develop and commercialize patented foundation AI model 'LENSai'
Precision Medicine
Jun 25, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jun 25, 2024

BioStrand collaborates with PGxAI to develop and commercialize patented foundation AI model 'LENSai'

Partnerships

  • BioStrand has announced its collaboration with PGxAI to develop and commercialize its patented foundation AI model, LENSai.

  • As part of the partnership, PGxAI will support the commercial rollout of the LENSai Application Programming Interface (API) by expanding product features and market reach. This collaboration addresses problems when analyzing and interpreting large amounts of genetic information. LENSai will be an advanced tool that processes LLMs, research, and patient data, enabling custom treatments to improve patient outcomes. 

  • BioStrand, a subsidiary of ImmunoPrecise Antibodies (IPA), is a Belgium-based biotechnology company specializing in genomic analysis and biotherapeutic discovery. It has developed a novel methodology to identify similarities and variations in genetic data. The company's proprietary HYFT technology enables the detection of unique fingerprints in biological sequences, facilitating advanced genomic research and precision medicine applications. BioStrand's offerings include AI-driven tools for sequence retrieval, drug development, and agricultural biotech.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.